Cara Therapeutics Overview
- Year Founded
-
2004
- Status
-
Acquired/Merged
- Employees
-
55
- Latest Deal Type
-
M&A
- Investors
-
1
Cara Therapeutics General Information
Description
Developer of a biotechnology research platform designed to discover and develop immunotherapy treatments for cancers that resist existing immune-based therapies. The company offers epigenetic drug discovery, preclinical research, tumor microenvironment reprogramming, immunotherapy combination development, and therapeutic validation capabilities, enabling pharmaceutical companies and research institutions to advance cancer treatment development and improve the effectiveness of immunotherapy approaches.
Contact Information
Website
www.caratherapeutics.comCorporate Office
- 4 Stamford Plaza
- 107 Elm Street, 9th Floor
- Stamford, CT 06902
- United States
Corporate Office
- 4 Stamford Plaza
- 107 Elm Street, 9th Floor
- Stamford, CT 06902
- United States
Cara Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 15. Merger/Acquisition | 15-Apr-2025 | Completed | Generating Revenue | |||
| 14. PIPE | 15-Oct-2020 | Completed | Generating Revenue | |||
| 13. Secondary Transaction - Open Market | Completed | Generating Revenue | ||||
| 12. PIPE | 20-Aug-2019 | Completed | Generating Revenue | |||
| 11. 2PO | 29-Jul-2019 | Completed | Generating Revenue | |||
| 10. Secondary Transaction - Open Market | 18-Apr-2016 | Completed | Generating Revenue | |||
| 9. Secondary Transaction - Open Market | 17-Apr-2015 | Completed | Generating Revenue | |||
| 8. IPO | 31-Jan-2014 | Completed | Generating Revenue | |||
| 7. Later Stage VC | $8M | $68.4M | Completed | Generating Revenue | ||
| 6. Later Stage VC (Series D) | 31-Jan-2013 | $2.9M | $60.4M | Completed | Generating Revenue |
Cara Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Junior A | ||||||||
| Junior Preferred | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B | 2,254,417 | $0.001000 | $2 | $2 | 1x | $1.84 | 6.85% | |
| Series A | 1,677,118 | $0.001000 | $1 | $1 | 1x | $1 | 4.69% |
Cara Therapeutics Comparisons
Industry
Financing
Details
Cara Therapeutics Competitors (38)
One of Cara Therapeutics’s 38 competitors is CytomX Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Prothena | Corporation | Dublin, Ireland | ||||
| Cerecin | Venture Capital-Backed | Broomfield, CO | ||||
| Baliopharm | Venture Capital-Backed | Basel, Switzerland | ||||
| Elevar Therapeutics | Formerly VC-backed | Fort Lee, NJ |
Cara Therapeutics Signals
Cara Therapeutics Former Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alta Partners | Venture Capital | Minority | ||
| Amzak Health | Venture Capital | Minority | ||
| Ascent Biomedical Ventures | Venture Capital | Minority | ||
| CSL Vifor | Corporation | Minority | ||
| Connecticut Innovations | Venture Capital | Minority |
Cara Therapeutics Acquisitions (1)
Cara Therapeutics’s most recent deal was a Reverse Merger with Tvardi Therapeutics. The deal was made on 15-Apr-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Tvardi Therapeutics | 15-Apr-2025 | Reverse Merger | Drug Discovery |
Cara Therapeutics ESG
Risk Overview
Risk Rating
Updated April, 30, 2024
28.97 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,744
Rank
Percentile
Pharmaceuticals
Industry
of 853
Rank
Percentile
Biotechnology
Subindustry
of 369
Rank
Percentile
Cara Therapeutics FAQs
-
When was Cara Therapeutics founded?
Cara Therapeutics was founded in 2004.
-
Where is Cara Therapeutics headquartered?
Cara Therapeutics is headquartered in Stamford, CT.
-
What is the size of Cara Therapeutics?
Cara Therapeutics has 55 total employees.
-
What industry is Cara Therapeutics in?
Cara Therapeutics’s primary industry is Drug Discovery.
-
Is Cara Therapeutics a private or public company?
Cara Therapeutics is a Private company.
-
What is Cara Therapeutics’s current revenue?
The current revenue for Cara Therapeutics is .
-
How much funding has Cara Therapeutics raised over time?
Cara Therapeutics has raised $319M.
-
Who are Cara Therapeutics’s investors?
Alta Partners, Amzak Health, Ascent Biomedical Ventures, CSL Vifor, and Connecticut Innovations are 5 of 14 investors who have invested in Cara Therapeutics.
-
Who are Cara Therapeutics’s competitors?
CytomX Therapeutics, Prothena, Cerecin, Baliopharm, and Elevar Therapeutics are some of the 38 competitors of Cara Therapeutics.
-
When was Cara Therapeutics acquired?
Cara Therapeutics was acquired on 15-Apr-2025.
-
Who acquired Cara Therapeutics?
Cara Therapeutics was acquired by Tvardi Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process